Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BETRI-Prospective in uncontrolled adult asthma
2025-524289-56-00Phase 4Authorised
- Sponsor
- Chiesi Farmaceutici S.p.A.
- Start
- May 2026
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 4, randomised, open-label trial in asthma comparing Trimbow single-inhaler triple therapy with Fostair single-inhaler ICS/LABA (2 arms). Primary endpoint: Change from baseline in Asthma Control Questionnaire-5 score at Visit 7. Planned start May 2026; status: authorised.
02
Drugs
beclometasone dipropionate/formoterol fumarate/glycopyrroniumbeclometasone dipropionate + formoterol
03
Conditions
asthma
Beyond the preview
Go deeper on 2025-524289-56-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524289-56-00.